Gilead Pseudomonas

Trial Status: 
Current Trial - Enrollment Complete

A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States [AIR-CF5]


The purpose of this study is to investigate the development of drug resistance when using Cayston®.  Some bacteria—mainly Pseudomonas aeruginosa (PA)—will be taken from sputum and tested for any changes in drug resistance.  In addition, changes in health will be compared to changes in resistance.  The goal of this study is to determine whether there are any changes in resistance to aztreonam in PA from patients with CF over a five year period.


You may be eligible if you are over 18 years of age, have cystic fibrosis, and use Cayston for chronic Pseudomonas Aeruginosa infection.


Gilead Sciences

Principal Investigator: 

Cori Daines, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Principal Investigator: 
Research Area: 
Clinical and Population Research